Psyence Biomedical Ltd’s Post

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions!

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions! https://lnkd.in/dN3yhYTs

🚨 Acticor Biotech: Strategic Appointment and Clinical Developments! 🚨   We are sharing two major updates for Acticor Biotech :  🔹 Clinical Focus: Acticor Biotech is preparing the design for an upcoming GLORIA clinical trial, aimed at assessing glenzocimab's benefits in angioplasty for STEMI. Currently, 27 patients have been enrolled in the Phase 2b LIBERATE study, evaluating our innovative drug, glenzocimab, in the treatment of ST-Elevation Myocardial Infarction (STEMI).  🔗 : https://lnkd.in/edRtDvhX 🔹 Francois Guillet has been appointed as Chief Financial Officer. With his extensive experience in restructuring and international management, François will be a valuable asset in guiding Acticor Biotech through this strategic phase. We are thankful to Eric COHEN for his remarkable contributions since 2016, especially during Acticor's IPO. 🔗 : https://lnkd.in/ej3Y4Ukc #Biotech #innovation #clinicaldevelopment

Trusted by emerging #biotech, Medpace's Clinical Pharmacology Unit (MCPU) recently guided a Sponsor with no prior Phase I experience through a successful SAD/MAD trial. Our latest case study highlights how the MCPU's comprehensive support, embedded expertise, and collaborative model helped navigate the biotech through the complex challenges of early-phase development. Download the case study to see why biotech companies rely on Medpace for seamless early-phase development: https://lnkd.in/g4HfvXdF

“The incentives of CROs are currently totally misaligned with sponsors and with patients — CROs typically earn more money from projects that are delayed, due to their billable hour business model” Meri Beckwith, Co-founder of Lindus, the #AntiCRO #CRO, #eClinicalSolution, #Pharma, and #Biotech are all partners within the industry existing for the betterment of the public healthcare sector. As a representative of a company that exists solely as an #enabler, I believe we are heading, albeit with many twists and turns, in the right direction. That said, there are so many waves of change happening within our industry. #LindusHealth, along with many others in the industry, is proposing one of the slurry of interesting takes on the problem. #JNPMEDI #JNPMEDICONNECT #2023JNPMEDICONNECT #MAVEN #MavenClinicalCloud #MavenDCTSuite #DCT #DecentralizedClinicalTrials #DigitalClinicalTrials

#News: Evotec announced further progress of the company’s strategic partnership with Bristol Myers Squibb relating to building a #molecularglue-based pipeline, triggering a $75 million performance-based and program-based milestone payment to #Evotec.   Initiated in 2018, the partnership combines Evotec’s high-performance #multiomics #screening and #analytics capabilities with #BristolMyersSquibb’s library of #cereblon #E3 #ligasemodulators (CELMoDs). Expanded in 2022, the partnership continues to identify #novelmoleculargluedegraders, targeting high-value targets in the field of #oncology and beyond.    Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “Bristol Myers Squibb is leading the industry in the field of molecular glue degraders, which is clearly one of the most exciting emerging therapeutic modalities. Through our highly systematic and industrialized PanOmics-based approach the pipeline of molecular degraders addressing high value targets keeps growing and maturing. The breadth and the depth of the pipeline is designed to deliver multiple first-in-class products into the market. We are well on track to deliver on our plans.” 🕮 Read more from Contract Pharma 👉🏼 https://lnkd.in/eWgevNNg

The Digital Therapeutics Alliance (DTA) has addressed the cessation of Better Therapeutics' operations and its delisting from Nasdaq, marking a significant moment in the digital health industry. Jessica Hauflaire, DTA's Chief Operating Officer, highlighted the volatile nature of the healthcare innovation sector, acknowledging the challenges that companies like Better Therapeutics face, including regulatory, funding, market adoption, and clinical validation hurdles. Despite this setback, the DTA remains optimistic about the future of #digitalhealth, underscoring its potential to revolutionize patient care, outcomes, and healthcare efficiency through technology, data analytics, and AI. The Alliance calls for continued gratitude, determination, and optimism in advancing digital therapeutics, underscoring the collective effort required to overcome challenges and fully harness the transformative power of digital health (https://lnkd.in/e2gvWuch). The #bankruptcy of Better Therapeutics, following those of Pear Therapeutics and Dthera Sciences, brings to light the precarious yet potentially valuable position of DTx startups within the healthcare innovation landscape. The bankruptcy auction of Pear Therapeutics' assets, which concluded with a $6.05 million sale distributed among Click Therapeutics, Harvest BIO, Nox Health Group, and Welt, vividly illustrates the significant value placed on #intellectualproperty (IP), especially #patents within the DTx sector. Similarly, the acquisition of all Dthera Sciences' patents related to DTx for #Alzheimer’s disease by Telememory Holding Corp further emphasizes this point. These developments raise questions about the future of Better Therapeutics' patents, particularly those concerning DTx for #obesity and type 2 #diabetes, underscoring the critical role of IP in sustaining #innovation and competition in the digital health arena. The strategic acquisitions of Pear's and Dthera's IP assets reflect a broader trend within the DTx field, where patents are increasingly recognized not merely as legal protections but as key assets that drive innovation, expand therapeutic portfolios, and solidify a company's competitive edge in the burgeoning digital health market.

Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration, by Oxford Global features insights from leading experts at Discovery & Automate 2024. The report delves into cutting-edge technologies, tackles challenges in CNS drug discovery, and highlights the transformative impact of data-driven approaches. Report Highlights: # Integration of Advanced Technology in Drug Discovery: Explore how cutting-edge technologies are transforming the drug discovery process. # Challenges and Strategies in CNS Drug Discovery and Development: Gain insights into overcoming obstacles in CNS drug research. # Data-Driven Approaches & Predictive Modelling: Learn about the latest data-driven methodologies and predictive models shaping the future of drug discovery.

Meet Aris Perrou at the AE&T in London and discuss how PAIA Biotech GmbH can help you improve your early #developability screening efforts.👍 Great technology🚀 #antibodydiscovery #mAbs #antibodyengineering #innovation

Preclinical study protocols are foundational to the reports that regulatory bodies require. Therefore, the quality of your study protocols can make or break your study! Learn about the 13 elements you NEED to include in any preclinical study protocols in our latest blog post ➡️ https://hubs.la/Q02WMg6V0 #Preclinical #StudyProtocols #RegulatoryApproval #Medtech